Mizuho Markets Cayman LP Decreases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Mizuho Markets Cayman LP lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,168 shares of the life sciences company’s stock after selling 650 shares during the period. Illumina accounts for approximately 1.2% of Mizuho Markets Cayman LP’s holdings, making the stock its 17th biggest position. Mizuho Markets Cayman LP’s holdings in Illumina were worth $283,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after acquiring an additional 66,528 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Illumina by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after purchasing an additional 204,043 shares during the last quarter. Capital World Investors grew its stake in shares of Illumina by 41.1% in the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after buying an additional 801,814 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after buying an additional 1,997,010 shares during the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd raised its position in shares of Illumina by 1.1% during the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock valued at $284,097,000 after buying an additional 22,067 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank of Canada boosted their price objective on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Leerink Partners raised their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Barclays increased their target price on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Trading Down 5.1 %

NASDAQ:ILMN opened at $135.05 on Friday. The firm has a 50-day simple moving average of $139.66 and a 200-day simple moving average of $124.30. Illumina, Inc. has a one year low of $92.69 and a one year high of $156.66. The firm has a market cap of $21.42 billion, a P/E ratio of -13.56 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.33 earnings per share. Equities analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.